Revance Q1 product revenue $51.7M (+13% YoY); launches Daxxify for cervical dystonia

Revance Therapeutics, Inc.

2024-Q1 EPS reported -$0.58 revenue$51,936,000

Total net product revenue (DAXXIFY + RHA) $51.7M, up 13% YoY; DAXXIFY net $22.1M after $2M coupon.
DAXXIFY aesthetic units sold +105% YoY; toxin market share 3.7% (up from 3.0% in Q4).
Net loss from continuing ops $49.5M, comparable to $48.5M a year ago; cash $277.1M.
FY 2024 guidance: total net product revenue at least $280M; funded to cash-flow breakeven in 2025.
Launched DAXXIFY for cervical dystonia (CD), entering $2.7B U.S. therapeutic neurotoxin market; 78% commercial lives covered.

item 2.02 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Revance Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

Total net revenue for the first quarter ended March 31, 2024 was $51.9 million compared to $45.8 million for the same period last year, representing an increase of 13%, due to an increase in DAXXIFY sales volume.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Revance Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

Net loss from continuing operations for the first quarter ended March 31, 2024 was $49.5 million compared to $48.5 million for the same period in 2023.

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001479290-24-000099

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.